Shares of Precigen, Inc. (NASDAQ:PGEN - Get Free Report) reached a new 52-week high during trading on Wednesday . The stock traded as high as $2.17 and last traded at $2.02, with a volume of 2193081 shares. The stock had previously closed at $1.96.
Analysts Set New Price Targets
PGEN has been the topic of several recent analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $6.00 price target (up previously from $4.00) on shares of Precigen in a research note on Thursday, January 23rd. JMP Securities reaffirmed a "market outperform" rating and issued a $5.00 price target on shares of Precigen in a research note on Tuesday, January 14th. Two investment analysts have rated the stock with a sell rating and four have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $7.00.
Get Our Latest Research Report on Precigen
Precigen Stock Performance
The company's fifty day simple moving average is $1.25 and its 200-day simple moving average is $1.06. The company has a market capitalization of $559.38 million, a P/E ratio of -3.47 and a beta of 1.66.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Iridian Asset Management LLC CT grew its holdings in Precigen by 38.8% during the 4th quarter. Iridian Asset Management LLC CT now owns 5,241,922 shares of the biotechnology company's stock worth $5,871,000 after acquiring an additional 1,465,962 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Precigen by 1.6% in the 4th quarter. Geode Capital Management LLC now owns 3,299,851 shares of the biotechnology company's stock valued at $3,696,000 after buying an additional 53,343 shares in the last quarter. State Street Corp boosted its holdings in shares of Precigen by 1.0% in the 3rd quarter. State Street Corp now owns 2,872,064 shares of the biotechnology company's stock valued at $2,720,000 after buying an additional 29,253 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Precigen by 4.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,278,862 shares of the biotechnology company's stock valued at $1,432,000 after buying an additional 56,012 shares in the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of Precigen by 11.6% in the 4th quarter. Northern Trust Corp now owns 1,168,689 shares of the biotechnology company's stock valued at $1,309,000 after buying an additional 121,700 shares in the last quarter. 33.51% of the stock is currently owned by institutional investors.
About Precigen
(
Get Free Report)
Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.
See Also
Before you consider Precigen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Precigen wasn't on the list.
While Precigen currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
